Scientific deep-dive
Muscle Loss: Drug Versus Dieting
Across 20 trials in 15,782 people, the share of weight lost as lean mass was the same on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.
“These drugs make you lose muscle” is the most repeated criticism of GLP-1 medicines, and it is almost never accompanied by the comparison that would make it meaningful. A meta-analysis of 20 randomized trials in 15,782 people supplied it: the share of weight lost as lean mass on incretin drugs is broadly the same as on dieting.[1]
The comparison
| Intervention | Lean share of weight lost |
|---|---|
| Semaglutide | 35.2% (95% CI 31.5–38.9) |
| Liraglutide | 26.8% (95% CI 23.1–30.5) |
| Tirzepatide | 25.4% (95% CI 22.8–28.0) |
| Lifestyle intervention | 26.2% (95% CI 24.1–28.3) |
| Lifestyle plus resistance training | 17.5% (95% CI 14.2–20.8) |
The comparison between incretin drugs as a group and lifestyle intervention returned p=0.42 — no significant difference.[1] Losing weight costs lean tissue. It costs about the same proportion whether the weight comes off through a drug or through dieting.
The criticism is real and it is not specific to the drugs. It is a property of losing weight.
The row that actually helps
Adding resistance training brought the lean share down to 17.5% — the most favorable profile in the analysis, and the only intervention here that changes the answer rather than describing it.[1]
That is the practical conclusion, and it is the same one arrived at from a completely different direction in the exercise trial, where the drug alone did nothing for physical fitness and training did. Two independent lines of evidence, one instruction: lift something.
The difference between the drugs is not nothing
It would be convenient to flatten this into “all the same”, and the data do not allow it. Semaglutide sits at 35.2% and tirzepatide at 25.4%, and those confidence intervals do not overlap. Within the class, they differ.
What that means is genuinely unclear from this analysis. It could reflect the drugs, the speed of loss they produce, the trial populations, or how body composition was measured in each study — heterogeneity across the pooled trials was moderate. It is a real difference in the numbers and not yet an explained one, and it is not a reason to choose between them.
What lean mass does and does not tell you
Every figure above is a scan measurement. Whether the person can do more or less is a different question, and one that scans answer badly — we found a study where muscle volume fell 9.3% while chair-rise and walking speed both edged better, covered in muscle volume versus muscle function.
So the full picture is three-part: lean mass falls with any weight loss, at a similar proportion drug or diet; resistance training substantially reduces that share; and the mass number alone does not establish that anyone has been harmed.
Frequently Asked Questions
References
- 1.Eisa N, Barood O, et al. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Diabetes, Obesity and Metabolism. 2026. PMID: 41877354.
Related research
Exercise Plus a GLP-1: What Each One Actually Changes
In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise alone did. Both together did most — and the strength result needs reading carefully.
6 min read
Lifestyle Plus the Drug
Across 98,261 people, taking a GLP-1 and keeping six to eight healthy habits meant 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.
5 min read
Bimagrumab Plus Semaglutide: The Muscle Question
The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.
6 min read
Handgrip Strength and Sarcopenic Obesity
Over twelve months on semaglutide, handgrip strength rose 4.5 kg and sarcopenic obesity fell from 49% to 33% — while lean mass declined early then stabilized rather than continuing down.
5 min read
Muscle Volume Versus Muscle Function on a GLP-1
Psoas muscle volume fell 9.3% over 24 weeks while chair-rise time and walking speed both edged better. Mass and function moved in opposite directions in the same people — and only one of them is what anybody wants.
6 min read
Fat-to-Muscle Ratio: Surgery Versus Drugs
The lean-to-fat ratio improved in both groups at 6, 12 and 24 months. Everyone loses lean tissue when losing weight — the question is the mix, and both interventions improved it.
5 min read
Where to get semaglutide (Ozempic / Wegovy) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Try Ageless
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
From $99/mo
Get started →ShedRx
Oral orforglipron alongside the injectables
From $149/mo
Get started →